Palatin Technologies has started dosing patients in its Phase l clinical trial to assess the safety and tolerability of PL-8177 for the treatment of ulcerative colitis and other inflammatory bowel diseases.

Ulcerative colitis is a chronic disease of the large intestine, with inflammation and ulcerations that can cause symptoms such as significant abdominal pains, persistent diarrhoea and appetite loss.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The first-in-human clinical trial of PL-8177 is a randomised, double-blind, placebo-controlled, single and multiple ascending dose study.

“We currently anticipate additional compounds entering clinical development later this year.”

During the trial, PL-8177 will be administered through subcutaneous injection.

The trial aims to enrol up to 52 healthy volunteers and top-line data is expected by the third quarter of this year.

Palatin Technologies chief financial officer and chief operating officer Stephen Wills said: “This is a significant milestone for Palatin, as this is our second melanocortin peptide to enter clinical development.

“Beyond bremelanotide, for which we expect to file an NDA with the FDA for female sexual dysfunction later this quarter, we continue to expand our pipeline of novel peptide therapeutics targeting the melanocortin system.

“We are excited about the potential of our melanocortin receptor 1 (MC1r) peptides, which have the potential to treat a wide variety of inflammatory diseases.  We currently anticipate additional compounds entering clinical development later this year.”

Palatin’s PL-8177 is a synthetic cyclic heptapeptide that has shown efficacy in animal inflammatory bowel disease models.

The formulation is also a potent agonist at human MC1r, with sub-nanomolar affinity binding and EC50 functional values.